- Exchange: Copenhagen
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Snapshot for Genmab A/S (GEN)
| Open: | 187.7000 | Day's Range: | 186.0000 - 193.2000 | Volume: | 142,545 |
|---|---|---|---|---|---|
| Previous Close: | 191.5000 | 52wk Range: | 40.9700 - 204.5000 | 1-Yr Rtn: | +349.21% |
Key Statistics for GEN
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. KFX | - |
| Earnings Per Share (DKK) (ttm) | -0.5620 |
| Est. EPS (DKK) (12/2013) | -0.1980 |
| Est. PEG Ratio | - |
| Market Cap (M DKK) | 9,776.61 |
| Shares Outstanding (M) | 51.05 |
| 30 Day Average Volume | 230,596 |
| Price/Book (mrq) | 19.8943 |
| Price/Sale (ttm) | 16.2898 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/14/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for GEN
Company Profile & Key Executives for GEN
Genmab A/S is a biotechnology company. The Company creates and develops human antibody products for the treatment of life threatening and debilitating diseases. Genmab focuses on products to treat cancer, rheumatoid arthritis and other inflammatory conditions, and psoriasis. The Company develops new products through partnerships. Genmab operates in Europe and the United States.
| David A EatwellExec VP/CFO | Paul W H I ParrenSenior VP/Dir:Scientific |
| Michael K BauerSenior VP:Clinical Dvelopment | Anthony PaganoSenior VP:Global Finance |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
GEN News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page